Aim: The purpose of this study was to explore predictors of disability in patients with rheumatoid arthritis in Taiwan.
Background: Rheumatoid arthritis is a chronic inflammatory disease affecting mainly the joints. However, little information is currently available on the disability of Asian patients with rheumatoid arthritis.
Design: Cross-sectional survey.
Method: Patients (150) were recruited by convenience sampling from those regularly visiting rheumatologic outpatient clinics at three teaching hospitals and a medical centre in northern Taiwan. Data were collected on demographic and disease-related characteristics, depressive tendency, pain and disability using a basic patient-information form, the Center for Epidemiological Survey Depression Scale, Chinese version of the Brief Pain Inventory-short form and the Chinese version of the Health Assessment Questionnaire, respectively.
Results: Our sample had moderate pain severity (Mean = 4.32, SD 1.68) and pain disturbance (Mean = 3.49, SD 2.15). The mean disability score was 0.61 (SD 0.66), representing mild disability. Regression analysis revealed that patients' disability was significantly predicted by disease stage (stage IV, III, or II), depressive tendency, duration of disease and education level (primary school), explaining 79.2% of the total variance in disability.
Conclusion: The results of this study not only provide clinicians with predictive information of disability from rheumatoid arthritis, but also help them take suitable action on patients' depressive status according to their disability condition.
Relevance To Clinical Practice: The controllable predictor of disability in this study was depressive tendency. Thus, the authors recommend that clinicians regularly screen patients with rheumatoid arthritis for depressive tendency and teach self-care methods to minimise depressive symptoms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1365-2702.2010.03335.x | DOI Listing |
Chest
March 2025
University of Sousse, Faculty of Medicine of Sousse, Farhat HACHED Hospital, Heart Failure (LR12SP09) Research Laboratory, Sousse, Tunisia. Electronic address:
BMJ Open
March 2025
Zora Biosciences Oy, Espoo, Finland
Objectives: This study aimed to explore the association between lipid-based Cardiovascular Event Risk Tests (CERT1 and CERT2), including ceramides (Cer) and phosphatidylcholine (PC) lipid species, and rheumatoid arthritis (RA), an inflammatory disease that can increase the risk of cardiovascular diseases.
Design: Prospective population-based cohort study.
Setting: Primary care centres across five geographical areas in Finland.
Int J Biol Macromol
March 2025
Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic. Electronic address:
Frequent degenerative joint diseases, known as arthritis, are characterized by joint inflammation and cartilage breakdown. Various arthritis types are traditionally managed with intra-articular injections of hyaluronan or its derivatives. However, intravenous administration of hyaluronan is emerging as a vital alternative, particularly because intra-articular injections can be challenging for clinicians when targeting small or swollen joints.
View Article and Find Full Text PDFExp Cell Res
March 2025
Central Labs, King Khalid University, AlQura'a, Abha, Saudi Arabia; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia. Electronic address:
CS1 (SLAMF7), a pivotal immune receptor, plays a dual role in modulating immune responses in autoimmune diseases and cancer. In autoimmunity, aberrant CS1 signaling contributes to the activation of autoreactive lymphocytes, driving pathologies such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Conversely, in oncology, CS1 serves as a promising immunotherapeutic target, exemplified by the efficacy of the monoclonal antibody Elotuzumab in multiple myeloma.
View Article and Find Full Text PDFPhytomedicine
March 2025
Department of Rheumatology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, 230031, China; First Clinical Medical School, Anhui University of Chinese Medicine, Hefei, Anhui, 230038, China.
Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic synovitis and associated with high rates of disability and systemic damage. Jianpi Qingre Tongluo prescription (Huangqin Qingre Chubi Capsule, HQC), an herbal formula with abundant clinical applications, has played a definite role in both clinical and experimental studies of RA. However, the specific mechanisms by which HQC relieves inflammation in RA have not been fully elucidated.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!